Rigel spikes after peer reviewed data on leukemia drug

• Rigel Pharmaceuticals (NASDAQ:RIGL) added ~9% on Tuesday after announcing that the medical journal Blood Advances published data supporting Rezlidhia (olutasidenib), its FDA-approved treatment for acute myeloid leukemia (AML).
• In December, Rigel (RIGL) launched Rezlidhia after the FDA cleared the oral therapy for adults with relapsed/ refractory AML harboring a susceptible IDH1 mutation.
• In the article "Olutasidenib: from Bench to Bedside," published online in May, the authors discuss the preclinical and clinical development of olutasidenib and review the drug's positioning in the mIDH1 AML treatment space.
• The article marks the second publication on Rezlidhia in Blood Advances. In February, the journal published results from the Phase 2 registrational trial for the candidate in mIDH1 R/R AML.

More on Rigel

• Rigel Pharma begun at neutral at Piper Sandler on value creation potential
• Rigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive Growth